{"id":11438,"date":"2025-07-26T18:57:51","date_gmt":"2025-07-26T16:57:51","guid":{"rendered":"https:\/\/valintermed.com\/?p=11438"},"modified":"2025-07-26T18:57:51","modified_gmt":"2025-07-26T16:57:51","slug":"her-2-polozhitelnyy-rak-molochnoy-zhelezy","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/her-2-positive-breast-cancer\/","title":{"rendered":"HER-2 positive breast cancer"},"content":{"rendered":"
<\/div>\n

HER-2 positive breast cancer is a subtype of breast cancer characterized by excessive expression of the HER-2 (human epidermal growth factor receptor 2) protein on the surface of tumor cells. This protein belongs to the epidermal growth factor receptor family and is actively involved in the processes of cell growth and division. Increased quantitative expression of HER-2 is observed in approximately 20\u201330% patients with breast cancer and is associated with a more aggressive course of the disease, which is important to consider when choosing a treatment strategy and prognostic assessments. A scientifically based approach to the treatment of HER-2 positive cancer includes the use of specific targeted therapies, such as trastuzumab, which radically changes outcomes compared to traditional methods.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n